Diagnostic Imaging Partnering Terms and Agreements

Logo

Naperville, IL -- (SBWire) -- 08/07/2014 --Reportstack, provider of premium market research reports announces the addition of Diagnostic Imaging Partnering Terms and Agreements market report to its offering

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:

Imaging
CT
Endoscope
Molecular and nuclear
PET
SPECT
MRI
Ultrasound
X ray
Angiography
Fluoroscopy
Mammography

This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2009.

This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2009. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.

Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.

For example, analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostic imaging dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading diagnostic imaging deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of diagnostic imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of diagnostic imaging partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of diagnostic imaging partnering deals by specific imaging technology types announced since 2009. The chapter is categorized by deals including imaging, CT, Endoscope, Molecular and nuclear (PET, SPECT), MRI, Ultrasound, X-Ray (angiography, fluoroscopy, mammography). Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in diagnostic imaging partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by diagnostic imaging partnering by company A-Z , stage of development, deal type and therapy area. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostic imaging technologies and products.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.
Diagnostic Imaging Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to diagnostic imaging trends and structure of deals entered into by leading companies worldwide.

Diagnostic Imaging Partnering Terms and Agreements includes:

Trends in diagnostic imaging dealmaking in the biopharma industry since 2009
Analysis of diagnostic imaging deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life diagnostic imaging deals
Access to over 700 diagnostic imaging deal documents
The leading vaccine deals by value since 2009
Most active diagnostic imaging dealmakers since 2009
The leading diagnostic imaging partnering resources

In Diagnostic Imaging Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Therapy target
Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise vaccine rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/165903/diagnostic-imaging-partnering-terms-and-agreements.html

Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604

Media Relations Contact

Roger Campbell
Director of Marketing
http://www.reportstack.com

View this press release online at: http://rwire.com/536761